Department of Otorhinolaryngology, Benha Faculty of Medicine, Benha University, Egypt.
Department of Otorhinolaryngology, Benha Faculty of Medicine, Benha University, Egypt.
Am J Otolaryngol. 2021 Mar-Apr;42(2):102884. doi: 10.1016/j.amjoto.2020.102884. Epub 2021 Jan 4.
To evaluate the role of the topical corticosteroid, mometasone furoate, nasal spray in the treatment of post COVID-19 anosmia.
A prospective, randomized, controlled trial was conducted among patients with post COVID-19 anosmia. One hundred patients were randomly assigned to two groups; group I included 50 patients received mometasone furoate nasal spray in an appropriate dose of 2 puff (100 μg) once daily in each nostril for 3 weeks with olfactory training, group II included 50 patients were advised to keep on olfactory training only. The assessment of smell was done using (Visual Analog Scale from 0 to 10). All patients were initially evaluated after their recovery from COVID-19 and followed up for 3 weeks. The smell scores were recorded weekly and the duration of smell loss was recorded from the onset of anosmia till the full recovery.
In both groups, the smell scores significantly improved by the end of the third week (P < 0.001). By comparing smell scores between both groups after 1 week, 2 weeks, and 3 weeks of treatment, there were no statistically significant differences between both groups. In group I, (62%) of patients completely recovered their sense of smell after 3 weeks of treatment, compared to (52%) of patients in group II (P = 0.31).
The results suggested that using mometasone furoate nasal spray as a topical corticosteroid in the treatment of post COVID-19 anosmia offers no superiority benefits over the olfactory training, regarding smell scores, duration of anosmia, and recovery rates.
ClinicalTrials.gov ID: NCT04484493.
评估局部皮质类固醇糠酸莫米松鼻喷雾剂在治疗新冠后嗅觉丧失中的作用。
一项针对新冠后嗅觉丧失患者的前瞻性、随机、对照试验。100 名患者被随机分为两组；组 I 包括 50 名患者，他们接受糠酸莫米松鼻喷雾剂的适当剂量，每天每侧鼻孔喷 2 次（每次 100μg），持续 3 周，并进行嗅觉训练；组 II 包括 50 名患者，仅建议进行嗅觉训练。嗅觉评估使用（0 到 10 的视觉模拟量表）。所有患者在从新冠中康复后进行初始评估，并随访 3 周。每周记录嗅觉评分，从嗅觉丧失开始到完全恢复的时间记录嗅觉丧失的持续时间。
两组患者在第 3 周时嗅觉评分均显著改善（P < 0.001）。比较两组治疗 1 周、2 周和 3 周后的嗅觉评分，两组之间无统计学差异。在组 I 中，62%的患者在治疗 3 周后完全恢复嗅觉，而组 II 中为 52%（P = 0.31）。
结果表明，在治疗新冠后嗅觉丧失方面，使用糠酸莫米松鼻喷雾剂作为局部皮质类固醇，在嗅觉评分、嗅觉丧失持续时间和恢复率方面，与嗅觉训练相比没有优势。
ClinicalTrials.gov ID：NCT04484493。
